Oxybutynin Chloride in Managing Hot Flashes

Status Completed

Clinical Trial Summary

This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy. Previous studies have shown that oxybutynin is effective in managing hot flashes, however doses used in prior studies have resulted in side effects. This trial is evaluating lower doses of oxybutynin with the goal of determining if they are efficacious with less side effects.

ADAM-VTE

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine whether oxybutynin chloride (oxybutynin) can diminish hot-flash activity in women with a history of breast cancer or in women who have a concern about taking estrogen for fear of breast cancer.

SECONDARY OBJECTIVES:

I. To perform a dose-response evaluation of two oxybutynin doses. II. To determine the toxicity of oxybutynin in the study population. III. To assess the impact of hot-flash activity on overall quality of life and to examine whether oxybutynin can diminish this impact on quality of life.

OUTLINE: Patients are randomized into 1 of 4 groups.

GROUP I (LOW-DOSE OXUBUTYNIN CHLORIDE): Patients receive lower dose oxybutynin chloride orally (PO) twice a day (BID) on days 8-49 in the absence of unacceptable toxicity.

GROUP II (LOW-DOSE PLACEBO): Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.

GROUP III (HIGH-DOSE OXUBUTYNIN CHLORIDE): Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.

GROUP IV (HIGH-DOSE PLACEBO): Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02961790
Study type	Interventional
Source	Academic and Community Cancer Research United
Contact
Status	Completed
Phase	Phase 3
Start date	December 9, 2016
Completion date	April 27, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04996316` - MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals
Enrolling by invitation	`NCT05558917` - Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery	N/A
Active, not recruiting	`NCT05526872` - A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening	N/A
Not yet recruiting	`NCT05178498` - Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Recruiting	`NCT05544123` - The Treatment Situation of Chinese County Population With Breast Cancer
Withdrawn	`NCT05191004` - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC	Phase 1/Phase 2
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Recruiting	`NCT01462903` - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors	Phase 1
Completed	`NCT01422408` - Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy	Phase 2
Terminated	`NCT00770354` - Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer	Phase 2
Terminated	`NCT02810873` - Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer	N/A
Withdrawn	`NCT03185871` - Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses	Phase 2
Completed	`NCT02983279` - Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer	N/A
Active, not recruiting	`NCT02194387` - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members	N/A
Recruiting	`NCT05406232` - Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Recruiting	`NCT03408353` - Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
Completed	`NCT01641068` - Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms	N/A
Withdrawn	`NCT04190433` - Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial	Phase 2
Recruiting	`NCT04799535` - Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Terminated	`NCT02923037` - Hatha Yoga in Breast Cancer Survivors	N/A